You are here: Industry Insights > Imbruvica

News List

Imbruvica, Rituxan Combination sNDA Accepted for Review by FDA americanpharmaceuticalreview
June 27, 2018
AbbVie announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for Imbruvica (ibrutinib) in combination with rituximab (Rituxan) as a new treatment option for Waldenström's macroglo
AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks fiercepharma
May 28, 2018
AbbVie’s Imbruvica growth strategy in chronic lymphocytic leukemia centers on expanding use of the drug among previously untreated patients. And it now has some new data that should help it do that.
Scientists discover ‘Achilles’ heel’ of oesophageal cancer pharmafile
August 24, 2017
Researchers from The Institute of Cancer Research have potentially found a new use for Imbruvica, after discovering a weakness in certain types of oesophageal cancer.
AbbVie/Janssen’s Imbruvica filed for graft-versus-host-disease pharmatimes
April 07, 2017
US regulators have agreed to review AbbVie and Janssen’s Imbruvica for previously treated chronic ...
Imbruvica gets US nod for marginal zone lymphoma pharmatimes
January 23, 2017
Janssen and AbbVie's Imbruvica has been cleared by regulators in the US to treat certain patients with marginal zone lymphoma (MZL), a rare form of non-Hodgkin's lymphoma.

Previous page 1 2 3 Next page